Virax Biolabs
VRAX
3 hedge funds and large institutions have $12.5K invested in Virax Biolabs in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.27% less ownership
Funds ownership: 0.3% → 0.03% (-0.27%)
25% less funds holding
Funds holding: 4 → 3 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
94% less capital invested
Capital invested by funds: $195K → $12.5K (-$183K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$13.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$178K |
| 2 |
VF
Virtu Financial
New York
|
-$16K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$93 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $10.6K | +$13.8K | +591 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $1.85K | +$1.77K | +76 | +281% |
|
|
3
Wells Fargo
San Francisco,
California
| $72 | -$93 | -4 | -50% |
|
|
AC
4
Armistice Capital
New York
| – | -$178K | -4,880 | Closed |
|
|
VF
5
Virtu Financial
New York
| – | -$16K | -426 | Closed |
|
VRAX Hedge Fund Activity: Q1 2024 in Review
3 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q1 2024, worth a combined $12.5K — down 94% from $195K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of VRAX and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $13.8K. The largest seller was Armistice Capital, exiting entirely with an estimated $178K sold.
- 3 institutional investors held Virax Biolabs (VRAX) as of Q1 2024, down from 4 in Q4 2023.
- Funds reported $12.5K of Virax Biolabs stock for Q1 2024, down 94% quarter-over-quarter.
- 1 fund opened new Virax Biolabs positions in Q1 2024 and 2 closed out, a net change of -1 holder.
- The largest Virax Biolabs buyer in Q1 2024 was Citadel Advisors, an estimated $13.8K added.
- The largest Virax Biolabs seller in Q1 2024 was Armistice Capital, an estimated $178K sold.
Based on aggregated 13F filings for Q1 2024.